Quantitative results in this cohort of patients indicate that [161Tb]Tb-PSMA-617 provides notably higher absorbed dose to tumor lesions in comparison to [177Lu]Lu-PSMA-617. This evidence concerns the gene FOLH1 and neoplasm.